My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

4.020 -0.040 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and Discovery 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Preview: Cytek Biosciences's Earnings
 
Via Benzinga
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design 
From Cytek Biosciences, Inc.
Via GlobeNewswire
DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Cytek Biosciences Reports First Quarter 2025 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
 
Via Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
 
Via Benzinga
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Nasdaq Surges Over 500 Points; Johnson Controls Earnings Top Views
 
Via Benzinga
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Mercury Systems Posts Strong Results, Joins ArcBest, Tesla, Kennametal, Qualys And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.